GlassScriptPhysician profile
Barney B Parson
NPI 1730603689
$6,294.61
in general payments reported to CMS, 2019-2025
26 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $155 · 2022: $347 · 2023: $1,116 · 2024: $2,192 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,769 · Education: $24.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,768.98 |
| Education | $24.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,643.00 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $605.34 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $547.43 | 2021-2025 | Ingrezza |
| Abbvie INC. | $523.40 | 2023-2025 | |
| Axsome Therapeutics, INC. | $444.58 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $417.24 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $405.68 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $393.70 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $220.68 | 2022-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $142.23 | 2021-2025 | Fanapt |
| Lundbeck LLC | $137.66 | 2023-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $113.43 | 2021-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $112.04 | 2024-2025 | Invega Sustenna, Spravato |
| Tris Pharma INC | $81.61 | 2022-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $77.04 | 2022-2025 | Adzenys Xr-Odt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $73.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.52 | 2023-2024 | Trintellix |
| Collegium Pharmaceutical, INC. | $68.26 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $55.93 | 2021 | |
| Bausch Health US, LLC | $47.55 | 2022 | |
| Almatica Pharma LLC | $35.27 | 2024 | Loreev Xr |
| Harmony Biosciences LLC | $22.48 | 2025 | |
| Sunovion Pharmaceuticals INC. | $16.19 | 2022 | |
| Avanir Pharmaceuticals, INC. | $15.50 | 2021 | |
| Noven Therapeutics, LLC | $14.03 | 2024 | Secuado, Xelstrym |
| Merck Sharp & Dohme LLC | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barney Parson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.